3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
2
Phase 3
1
Status
Terminated
5
Withdrawn
1
Sponsor Class
INDUSTRY
5
Study Type
Interventional
5
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Breast
1
Conditions
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Breast Cancer Metastatic
1
Adenocarcinoma Gastric
1
Interventions
Cyclophosphamide
166
Docetaxel
154
Bevacizumab
153
Carboplatin
148
Gemcitabine
146
Cisplatin
146
pembrolizumab
144
Radiotherapy
135
Paclitaxel
132
Capecitabine
122
Rituximab
115
Oxaliplatin
104
Fluorouracil
103
Nivolumab
94
Irinotecan
85
Doxorubicin
85
Pemetrexed
83
Leucovorin
82
Dexamethasone
82
fludarabine
74
fludarabine phosphate
72
Bortezomib
69
Etoposide
67
Erlotinib Hydrochloride
66
Cetuximab
65
Methotrexate
58
Trastuzumab
56
Cytarabine
54
Lenalidomide
50
Everolimus
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
tusamitamab ravtansine
×
Clear all
NCT04524689
2025-10-29
CARMEN-LC05
Sanofi
Phase 2
Terminated
57 enrolled
26 charts
NCT04659603
2025-10-01
CARMEN-BT01
Sanofi
Phase 2
Terminated
50 enrolled
20 charts
NCT05245071
2025-08-29
CARMEN-LC06
Sanofi
Phase 2
Terminated
22 enrolled
11 charts
NCT05071053
2025-08-22
CARMEN-GC01
Sanofi
Phase 2
Terminated
35 enrolled
14 charts
NCT04394624
2025-06-06
CARMEN-LC04
Sanofi
Phase 2
Terminated
31 enrolled
22 charts